US › Healthcare

Palisade Bio Inc (PALI)

US · Healthcare · Biotechnology

$2.07+6.70%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-9.6M
Profit YoY
-330.5%
EPS
$-0.05
EPS estimate
$-0.04

EPS came in at -0.05 against a street estimate of -0.04 — a miss of 14.5%.

Key statistics

Market cap
$337.1M
P/E
16.2
Forward P/E
0.0
P/B
2.59
Book value
$0.76
EPS (TTM)
$0.12
52-week high
$2.86
52-week low
$0.53
50-day MA
$1.93
200-day MA
$1.92
Beta
1.54

Analyst view

Analysts rate Palisade Bio Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.22.

Shareholding

Insiders
1.64%
Institutions
94.37%

Largest institutional holders

FundStake
Ameriprise Financial Inc6.62%
B Group, Inc6.57%
HHG PLC6.15%
Octagon Capital Advisors LP5.91%
Perceptive Advisors LLC5.14%
COMMODORE CAPITAL LP4.13%
RA Capital Management, LLC4.10%
Franklin Resources Inc3.33%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Palisade Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.